Welcome to the Newsroom
17 October 2017
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) announces that new data investigating the use of eftilagimod alpha (IMP321), the Company’s lead product candidate, in combination with pembrolizumab in metastatic melanoma patients in Australia that have had either no response or a suboptimal response to pembrolizumab, will be presented in a poster presentation for the first time at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting.
Article as pdf